Fabry Disease pathophysiology in adults
Fabry disease is a rare, inherited lysosomal storage disorder characterized by the deficient activity of the enzyme alpha-galactosidase A. This enzymatic deficiency leads to the accumulation of globotriaosylceramide (Gb3) within various cell types, disrupting normal cellular functions and progressively damaging multiple organ systems. In adults, the pathophysiology of Fabry disease manifests through a cascade of cellular and tissue-specific alterations that underpin the clinical spectrum observed in this population.
At its core, the deficiency of alpha-galactosidase A results in the intracellular build-up of Gb3, primarily within endothelial cells, smooth muscle cells, cardiomyocytes, renal podocytes, and neurons. This accumulation disrupts cellular homeostasis by impairing membrane trafficking, promoting oxidative stress, and inducing inflammatory responses. The endothelial cell damage is particularly significant, as it compromises vascular integrity and function, leading to a range of vascular complications. The buildup of Gb3 within the vascular endothelium fosters a pro-inflammatory state, promotes cellular apoptosis, and results in endothelial dysfunction. These changes contribute to the development of microvascular and macrovascular disease, including stroke, coronary artery disease, and peripheral vascular disease.
In the cardiovascular system, Gb3 accumulation in cardiomyocytes leads to progressive hypertrophy, which is often a hallmark finding in adult Fabry patients. This hypertrophy can result in arrhythmias, heart failure, and other cardiac complications. The infiltration of Gb3 into renal cells causes glomerular sclerosis and tubulointerstitial fibrosis, impairing kidney function over time and potentially leading to end-stage renal disease. Additionally, Gb3 deposits in the nervous system cause small fiber neuropathy, resulting in pain, abnormal temperature regulation, and other neurological symptoms.
The pathophysiology also involves complex interactions between cellular apoptosis, oxidative stress, and inflammatory pathways. Gb3 accumulation triggers the production of reactive oxygen species (ROS), which damage cellular components and further exacerbate tissue injury. The inflammatory response, characterized by cytokine release and immune cell infiltration, facilitates ongoing tissue destruction and fibrosis, contributing to the progressive nature of organ damage in untreated individuals.
In adults, the disease progression is typically insidious, with many patients remaining asymptomatic or presenting with nonspecific symptoms for years. As the disease advances, clinical manifestations become more apparent, including characteristic acroparesthesias, angiokeratomas, hypohidrosis, and progressive organ dysfunction. The variability in symptom severity and organ involvement is influenced by the specific GLA gene mutations, residual enzyme activity, and environmental factors.
Understanding the pathophysiology of Fabry disease in adults underscores the importance of early diagnosis and intervention. Enzyme replacement therapy (ERT) and chaperone therapies aim to reduce Gb3 accumulation, mitigate cellular damage, and prevent or slow organ deterioration. Ongoing research continues to elucidate the molecular pathways involved, offering hope for more targeted and effective treatments in the future.